

The Optimal Dose of Prophylactic Intravenous Naloxone in Ameliorating Opioid-Induced Side Effects in Children Receiving Intravenous Patient-Controlled Analgesia Morphine for Moderate to Severe Pain: A Dose Finding Study

Constance L. Monitto, MD,* Sabine Kost-Byerly, MD,* Elizabeth White, RN,* Carlton K. K. Lee, PharmD,†‡ Michelle A. Rudek, PharmD, PhD,§ Carol Thompson, MS, MBA,|| and Myron Yaster, MD*‡

BACKGROUND: Opioid-induced side effects, such as pruritus, nausea, and vomiting are common and may be more debilitating than pain itself. A continuous low-dose naloxone infusion (0.25 $\mu\text{g}/\text{kg}/\text{h}$) ameliorates some of these side effects in many but not all patients without adversely affecting analgesia. We sought to determine the optimal dose of naloxone required to minimize opioid-induced side effects and to measure plasma morphine and naloxone levels in a dose escalation study.

METHODS: Fifty-nine pediatric patients (24 male/35 female; average age 14.2 ± 2.2 years) experiencing moderate to severe postoperative pain were started on IV patient-controlled analgesia morphine (basal infusion 20 $\mu\text{g}/\text{kg}/\text{h}$, demand dose 20 $\mu\text{g}/\text{kg}$, 5 doses/h) and a low-dose naloxone infusion (initial cohort: 0.05 $\mu\text{g}/\text{kg}/\text{h}$; subsequent cohorts: 0.10, 0.15, 0.25, 0.40, 0.65, 1, and 1.65 $\mu\text{g}/\text{kg}/\text{h}$). If 2 patients developed intolerable nausea, vomiting, or pruritus, the naloxone infusion was increased for subsequent patients. Dose/treatment success occurred when 10 patients had minimal side effects at a naloxone dose. Blood samples were obtained for measurement of plasma morphine and naloxone levels after initiation of the naloxone infusion, processed, stored, and measured by tandem mass spectrometry with electrospray positive ionization.

RESULTS: The minimum naloxone dose at which patients were successfully treated with a <10% side effect/failure rate was 1 $\mu\text{g}/\text{kg}/\text{h}$; cohort size varied between 4 and 11 patients. Naloxone was more effective in preventing pruritus than nausea and vomiting. Concomitant use of supplemental medicines to treat opioid-induced side effects was required at all naloxone infusion rates. Plasma naloxone levels were below the level of assay quantification (0.1 ng/mL) for infusion rates ≤ 0.15 $\mu\text{g}/\text{kg}/\text{h}$. At rates >0.25 $\mu\text{g}/\text{kg}/\text{h}$, plasma levels increased linearly with increasing infusion rate. In each dose cohort, patients who failed therapy had comparable or higher plasma naloxone levels than those levels measured in patients who did not fail treatment. Plasma morphine levels ranged between 3.52 and 172 ng/mL, and >90% of levels ranged between 10.2 and 61.6 ng/mL. Plasma morphine levels were comparable between patients who failed therapy and those patients who achieved symptom control.

CONCLUSIONS: Naloxone infusion rates ≥ 1 $\mu\text{g}/\text{kg}/\text{h}$ significantly reduced, but did not eliminate, the incidence of opioid-induced side effects in postoperative pediatric patients receiving IV patient-controlled analgesia morphine. Patients who failed therapy generally had plasma naloxone and morphine levels that were comparable to those who had good symptom relief suggesting that success or failure to ameliorate opioid-induced side effects was unrelated to plasma levels. (Anesth Analg 2011;113:834–42)

In patients of all ages, opioids are the analgesics most frequently prescribed for the management of moderate to severe pain. Regardless of their method of administration, all opioids produce undesired side effects, including nausea and vomiting, pruritus, constipation, urinary

retention, respiratory depression, cognitive impairment, opioid-induced hyperalgesia, dependence, and tolerance. Some of these side effects, such as nausea, vomiting, pruritus, and opioid-induced bowel dysfunction are common and can be so debilitating that patients would rather

From the *Department of Anesthesiology and Critical Care Medicine, Division of Pediatric Anesthesiology and Critical Care Medicine; †Department of Pharmacy; ‡Department of Pediatrics; and §Department of Oncology, Division of Chemical Therapeutics, The Johns Hopkins University School of Medicine, Baltimore; and ||Department of Biostatistics, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

Accepted for publication June 17, 2011.

Funding: Richard J. Traystman Endowed Chair.

The authors declare no conflicts of interest.

Reprints will not be available from the authors.

Address correspondence to Constance L. Monitto, MD, Department of Anesthesiology and Critical Care Medicine, Division of Pediatric Anesthesiology and Critical Care Medicine, The Johns Hopkins University School of Medicine, 600 North Wolfe St., Blalock 904, Baltimore, MD 21287. Address e-mail to cmonitt1@jhmi.edu.

Copyright © 2011 International Anesthesia Research Society

DOI: 10.1213/ANE.0b013e31822c9a44

be in pain than experience the consequences of opioid therapy. Additionally, physicians are often reluctant to prescribe opioids because of these side effects and because of their fear of other less common, but more serious complications such as respiratory depression. Indeed, the amelioration or elimination of these side effects is increasingly one of the most important challenges in acute pain management.

Naloxone, a μ -opioid receptor antagonist, is effective at reducing and antagonizing both desired and undesired opioid effects. The coadministration of low-dose naloxone (0.25 $\mu\text{g}/\text{kg}/\text{h}$) with opioid analgesics has shown promise as a method of ameliorating undesired side effects, specifically pruritus, and nausea and vomiting, without impairing the quality of analgesia.¹ Indeed, we previously demonstrated the success of this technique in children and adolescents receiving IV morphine to treat moderate to severe postoperative pain.² Inclusion of a low-dose naloxone infusion decreased the incidence of pruritus from 77% to 20% and the incidence of nausea from 70% to 35% in children and adolescents receiving IV patient-controlled analgesia (PCA) after surgery.² However, in that study, more than one-third of patients still experienced intolerable opioid-related side effects despite the use of low-dose naloxone. Because this prior study tested only 1 naloxone infusion rate, we did not know if either a smaller or larger dose might more effectively decrease the incidence of opioid-induced side effects in our patients, or if treatment failure could be explained in individual patients by subtherapeutic naloxone or increased morphine plasma levels.

Thus, the primary purpose of this study was to use a dose escalation study method to determine the naloxone infusion rate that would most effectively reduce the incidence of intolerable opioid-induced side effects (failure rate <10%) without affecting analgesia or opioid analgesic requirements in pediatric patients receiving IV PCA morphine. Our secondary aim was to measure plasma levels of morphine and naloxone at each of the naloxone infusion rates used, to determine whether specific naloxone or morphine plasma levels correlated with therapeutic success or failure.

METHODS

After obtaining IRB approval, written parental informed consent, and, when applicable, written patient assent, patients older than 6 and younger than 18 years of age, with acute, moderate to severe postoperative pain were enrolled and studied. Exclusion criteria included patients who remained tracheally intubated postoperatively, who required preoperative benzodiazepine administration, who were unable to communicate verbally, or who were unable to initiate a bolus (demand) dose via the PCA device as a result of mental or physical disability. Additionally, patients who were allergic to opioids, were in any investigational drug trial within 1 month of the treatment day of the study, who had received opioids within 7 days of the study, or who had a parent with a psychiatric illness that impaired their ability to provide consent were also excluded. Surgical procedures included posterior spinal fusion and pectus excavatum repair. Patients were recruited by a study

investigator before surgery, and the study protocol was instituted in the immediate postoperative period.

Although intraoperative general anesthetic management was not standardized, all patients enrolled in this study underwent general anesthesia during which they were routinely monitored, paralyzed with nondepolarizing muscle relaxants, and endotracheally intubated. After antagonism of neuromuscular blockade with neostigmine and atropine or glycopyrrolate, patients' tracheas were extubated and patients were transported to either the pediatric postanesthesia care unit or the pediatric intensive care unit for recovery. Upon arrival, patients were started on IV PCA (CADD®-Solis; Smiths Medical, St. Paul, MN). The PCA pump cassette contained 100 mg morphine sulfate in 100 mL normal saline (1 mg/mL). The following routine settings were established: an initial loading dose of up to 100 $\mu\text{g}/\text{kg}$ or more to achieve patient comfort, a maintenance basal infusion rate of 20 $\mu\text{g}/\text{kg}/\text{h}$, a demand dose of 20 $\mu\text{g}/\text{kg}$, a lockout time interval of 8 minutes, and a maximum of 5 doses per hour (maximum hourly morphine 0.12 mg/kg).

Naloxone was administered by a continuous infusion pump "piggy-backed" into the patient's IV catheter. The naloxone solution was prepared using a standard naloxone infusion consisting of 2 mg naloxone in 250 mL 0.9% saline (final concentration = 8 $\mu\text{g}/\text{mL}$).² The initial naloxone infusion rate evaluated (cohort 1) was chosen to be 0.05 $\mu\text{g}/\text{kg}/\text{h}$. This dose was doubled for the second cohort (0.10 $\mu\text{g}/\text{kg}/\text{h}$). Subsequent infusion rates were defined as the sum of the prior 2 infusion rates (0.10, 0.15, 0.25, 0.40, 0.65, 1, and 1.65 $\mu\text{g}/\text{kg}/\text{h}$, respectively).

Every 4 hours while awake, patients were evaluated by their bedside nurse for the presence and severity of pain and opioid-related side effects. Subjective pain scores were assessed using self-report, either the Wong-Baker FACES™ scale,³ or, in older children, a numerical 0 to 10 scale.⁴ Patients were also assessed by a study nurse to determine side effect severity. They were asked to self-assess pruritus and nausea (0 = none, 1 = present but tolerable, 2 = severe, intolerable), and if they had vomited. In addition, bedside nursing flow sheets were scrutinized for documented episodes of nausea and/or vomiting. Vital signs, including arterial blood pressure, respiratory rate, and oxyhemoglobin saturation were monitored and recorded every 4 hours.

Use of "rescue" antiemetics and antipruritics, opioid consumption, and the occurrence of respiratory depression were recorded. Patients who developed opioid-induced side effects were treated symptomatically by a protocol-driven algorithm. Nausea and/or vomiting was treated with IV dolasetron 0.35 mg/kg (maximum dose 12.5 mg) every 8 hours or ondansetron 0.1 mg/kg (maximum dose 4 mg) every 4 hours as needed. IV diphenhydramine 1 mg/kg (maximum dose 50 mg) every 4 to 6 hours was used as a second-line antiemetic rescue therapy and the primary antidote to treat pruritus. If these maneuvers did not relieve the patient's symptoms, the study was terminated, and the IV naloxone infusion was increased to 1 $\mu\text{g}/\text{kg}/\text{h}$. The amount of morphine used and the requirements for supplemental analgesia or symptomatic treatment during the 24-hour study period were recorded. Finally, if respiratory depression occurred (respiratory rate <8 breaths/

Table 1. Patient Demographics

Naloxone infusion rate ($\mu\text{g}/\text{kg}/\text{h}$)	No. of subjects (success/failure)	Age (y) (mean \pm SEM)	Sex, male/female	Posterior spine fusion/pectus excavatum	Cause of failure
0.05	5 (3/2)	12.7 \pm 2.5	3/2	3/2	P \times 1, N/V and P \times 1
0.10	5 (3/2)	16.9 \pm 1.3	3/2	1/4	P \times 2
0.15	11 (9/2)	15.0 \pm 2.1	5/6	10/1	P \times 2
0.25	4 (2/2)	13.6 \pm 2.0	0/4	4/0	P \times 1, N/V \times 1
0.40	8 (6/2)	15.1 \pm 1.5	3/5	7/1	P \times 1, N/V \times 1
0.65	5 (3/2)	13.3 \pm 1	3/2	2/3	P \times 2
1	11 (10/1)	14.2 \pm 2.5	7/4	9/2	N/V \times 1
1.65	10 (10/0)	13.8 \pm 2.3	0/10	10/0	None
Overall	59 (46/13)	14.4 \pm 2.2	24/35	36/13	P \times 9 N/V \times 3 N/V and P \times 1

N/V = nausea/vomiting; P = pruritus.

min, oxygen saturation $<90\%$, and the patient was unarousable), the IV PCA was to be turned off and the patient was ordered to receive naloxone $1 \mu\text{g}/\text{kg}$ IV as a bolus dose every minute until respiratory depression resolved.

Dose/treatment failure at any naloxone infusion rate occurred when 2 patients experienced intolerable side effects despite the naloxone infusion and the use of rescue medications. When this occurred, the naloxone infusion rate was increased for subsequent patients. Dose/treatment success and study completion occurred when 10 patients were successfully treated at a given dose with no more than 1 failure in that treatment cohort. The maximum number of patients in any cohort, therefore, was 11. After determining this minimum effective dose, the naloxone dose was increased 1 final time to determine whether a higher dose was associated with adverse events, such as reversal of analgesia as demonstrated by an increase in opioid consumption.

Serology

Blood samples (5 mL) were obtained from a dedicated indwelling IV catheter for measurement of plasma morphine, naloxone, and naloxone-3-glucuronide levels after initiation of the naloxone infusion, and at a later time point between 12 and 24 hours after the start of the infusion. Additionally, in patients who failed therapy, a blood sample was obtained before termination of the study. Blood samples were collected in EDTA-containing tubes and were processed within 30 minutes of collection by centrifugation for 10 minutes at $1500g$. The plasma supernatant was stored at -20°C until subsequent analysis using a validated liquid chromatography/tandem mass spectrometry method developed by the Kimmel Cancer Center at Johns Hopkins University Analytical Pharmacology Core Laboratory. Briefly, salirasib was extracted from plasma using acetonitrile precipitation. Separation of morphine, naloxone, and naloxone-3-glucuronide and the internal standard, morphine-(*N*-methyl- d_3), was achieved on a Waters XTerra[®] C-18 (3.5 μm , 150×2.1 mm internal diameter) analytical column using a mobile phase consisting of acetonitrile/2 mM ammonium acetate (65:35, v/v) containing 0.1% formic acid and an isocratic flow of 0.20 mL/min. The analytes were monitored by tandem mass spectrometry with electrospray positive ionization. Detection was performed by monitoring the ion transitions from m/z 286.0 \rightarrow 152.0 for morphine, 328.1 \rightarrow 310.0 for naloxone, 504.0 \rightarrow 310.0 for

naloxone-3-glucuronide, and 289.0 \rightarrow 152.0 for the internal standard. The linear calibration curves were generated over the range of 5 to 500 ng/mL for morphine and 0.1 to 10 ng/mL for naloxone. The presence of naloxone-3-glucuronide was qualitatively assessed. Plasma samples that were diluted 1:10 (v/v) with pooled plasma were accurately quantified. The accuracy and within- and between-day precision met the acceptance criteria for bio-analytical assays.⁵ An analytical run was deemed acceptable if 75% of calibrators tested were within $\leq 15\%$ from the nominal concentration ($\leq 20\%$ for the lower limit of quantification) and 66% of the quality controls tested were within $\leq 15\%$ from the nominal concentration.

Data Analysis

Patient characteristics, efficacy, plasma naloxone and morphine levels, and side effect scores were summarized by cohort level and over all cohorts. Data are presented as mean \pm SEM. Analyses between genders and dose categories on naloxone and morphine levels as well as pain scores were performed using regression analyses with robust estimates of standard errors. Similar analyses on side effects were performed with logistic regression.

RESULTS

Patient characteristics are displayed in Table 1. Overall, 59 patients participated in this study. There were 24 males and 35 females. One female and 11 males underwent repair of pectus excavatum, and the remaining 47 underwent posterior spinal fusion. Cohort size varied between 4 and 11 subjects. Thirteen patients were treatment failures (7 female, 6 male). The minimum naloxone infusion rate at which 10 patients were successfully treated with no more than 1 failure was $1 \mu\text{g}/\text{kg}/\text{h}$. Increasing the naloxone dose to $1.65 \mu\text{g}/\text{kg}/\text{h}$ resulted in no patients failing treatment because of intolerable side effects.

Naloxone was more effective in preventing pruritus than nausea and vomiting (Table 2). The overall incidence of pruritus was 27%, whereas only 2 of 21 patients reported any pruritus at naloxone doses $\geq 1 \mu\text{g}/\text{kg}/\text{h}$. Patients were next stratified into 3 naloxone dose ranges: low (0.05–0.15 $\mu\text{g}/\text{kg}/\text{h}$), moderate (0.25–0.65 $\mu\text{g}/\text{kg}/\text{h}$), and high (1–1.65 $\mu\text{g}/\text{kg}/\text{h}$). Naloxone infusion rates between 0.05 and 0.15 $\mu\text{g}/\text{kg}/\text{h}$ were grouped together as a low-dose cohort based on the observation that most previous studies have considered 0.25 $\mu\text{g}/\text{kg}/\text{h}$ as a low-dose infusion. Thus,

Table 2. Efficacy of Naloxone in Ameliorating Pruritus and Nausea and Vomiting

Naloxone infusion rate	No. of patients studied (success/failure)	Pruritus score = 0	Pruritus score = 1	Pruritus score = 2	N/V score = 0	N/V score = 1	N/V score = 2	Use of rescue antipruritic therapy	Use of rescue antiemetic therapy
Low	21 (15/6)	52%	29%	19%	55%	30%	15%	43%	43%
Moderate	17 (11/6)	76%	12%	12%	35%	41%	24%	24%	65%
High	21 (20/1)	90% ^a	10%	0%	48%	48%	4%	10% ^b	57%
Overall	59 (46/13)	73%	17%	10%	47%	40%	14%	25%	54%

N/V = nausea/vomiting.

^a The odds of pruritus was decreased by 88% at high-dose as compared with low-dose naloxone infusions ($P = 0.013$).

^b The odds of receiving rescue therapy (diphenhydramine) to treat pruritus was decreased by 86% at high-dose as compared with low-dose naloxone infusions ($P = 0.024$).




Figure 1. Plasma naloxone levels measured after 5 half-lives of naloxone infusion for subjects who achieved adequate symptom control (Rx success, ●) and subjects who failed therapy (Rx failure, ○) are shown. In treatment responders, average plasma naloxone levels increased linearly with increasing infusion rate (straight line, $R^2 = 0.76$). Patients who failed treatment (dashed line, — — —) had higher average plasma naloxone levels than those who did not fail treatment (comparison of slopes, $P = 0.009$). The minimum level of assay quantification, 0.1 ng/mL, is represented by a dash-dot-dot line (—●●—).

grouping these doses together allowed us to examine whether doses lower than the previously studied low dose might be effective. Infusion rates of 1 and 1.65 $\mu\text{g}/\text{kg}/\text{h}$ were cohorted together as high-dose naloxone because both doses led to treatment success. Comparing cohorts, we found that the odds of pruritus was decreased by 88% at high-dose as compared with low-dose infusions ($P = 0.013$). However, there was no difference in the incidence of nausea and vomiting among the 3 naloxone infusion cohorts. Overall, 47% of patients studied reported no nausea or vomiting, and 48% reported no nausea or vomiting at doses $\geq 1 \mu\text{g}/\text{kg}/\text{h}$. The incidence of severe side effects (pruritus or nausea/vomiting score = 2) did trend toward lower levels as naloxone infusion rate was increased. Severe pruritus occurred in 19%, 12%, and 0% of patients, whereas severe nausea/vomiting occurred in 15%, 24%, and 4% of patients, respectively. However, this trend did not reach statistical significance. Concomitant use of supplemental medicines to treat opioid-induced side effects was required at all naloxone infusion rates. Whereas the likelihood of receiving diphenhydramine to treat opioid-induced side effects was comparable across

all dose cohorts (48% vs 48% vs 39% for low-, moderate-, and high-dose cohorts, respectively), its use to specifically treat pruritus was significantly decreased in the high-dose naloxone cohort ($P = 0.024$). However, we found no difference in the use of rescue antiemetic therapy across dose cohorts (Table 2).

Naloxone-3-glucuronide, naloxone, and morphine plasma levels were measured for those patients who received naloxone infusions of $\geq 0.15 \mu\text{g}/\text{kg}/\text{h}$. Naloxone-3-glucuronide levels were below the measurement limits of the assay (0.1 ng/mL) for all samples tested. Plasma naloxone levels were below the measurement limits of the assay at an infusion rate of 0.15 $\mu\text{g}/\text{kg}/\text{h}$, and generally below assay limits at an infusion rate of 0.25 $\mu\text{g}/\text{kg}/\text{h}$. At infusion rates $>0.25 \mu\text{g}/\text{kg}/\text{h}$, in patients who achieved adequate symptom control, average plasma levels increased linearly with increasing infusion rate ($R^2 = 0.76$). At comparable naloxone infusion rates, patients who failed treatment had similar or higher plasma naloxone levels than mean plasma naloxone levels measured in those who did not fail treatment (comparison of slopes $P = 0.009$) (Fig. 1 and Table 3).

Average 24-hour morphine consumption was $1.41 \pm 0.08 \text{ mg}/\text{kg}/\text{d}$ and ranged from 1.13 ± 0.22 to $1.64 \pm 0.63 \text{ mg}/\text{kg}/\text{d}$ across cohorts (Table 3). Female subjects consumed significantly more morphine than males (1.57 ± 0.10 vs $1.17 \pm 0.12 \text{ mg}/\text{kg}/24 \text{ h}$, $P < 0.025$). However, observing each gender individually, we found no significant difference in 24-hour morphine consumption as a function of naloxone infusion dose cohort (Table 4).

Whereas the overall average plasma morphine level was $31.8 \pm 2.3 \text{ ng}/\text{mL}$ (Table 3), interindividual variability was moderately high with morphine levels ranging between a minimum of 3.52 and a maximum of 172 ng/mL (Fig. 2). However, $>75\%$ of measured plasma morphine levels decreased between 16 and 46 ng/mL, whereas $>90\%$ ranged between 10.2 and 61.6 ng/mL. Comparing plasma morphine levels between responders and treatment failures, we found that at the time the second plasma morphine level was measured (>12 hours after initiation of PCA and naloxone infusion), mean plasma morphine levels did not differ significantly between the 2 groups (34.7 ± 5.1 vs $29.2 \pm 3.2 \text{ ng}/\text{mL}$ for responders and treatment failures, respectively). In addition, the slopes of the lines correlating morphine plasma level and morphine consumption were approximately equal to zero, suggesting that morphine level was generally stable and independent of morphine consumption for patients in both groups. Finally, beyond

Table 3. Plasma Naloxone and Morphine Levels and 24-Hour Consumption for Naloxone Infusion Cohorts and Subjects Who Failed Therapy

Naloxone infusion rate ($\mu\text{g}/\text{kg}/\text{h}$)	Equilibrated ^a naloxone level (ng/mL)	Naloxone levels for treatment failures ^b (time measured)	Morphine level (ng/mL)	Morphine levels for treatment failures ^b (time measured)	24-Hour morphine consumption (mg/kg)
0.05	N/A	N/A	N/A	N/A	1.13 \pm 0.22
0.10	N/A	N/A	N/A	N/A	1.16 \pm 0.24
0.15	BLQ	BLQ (15 h, 18 h)	24.6 \pm 2.9	16.0, 30.0, 14.0 (15 h, 18 h, 22 h)	1.38 \pm 0.19
0.25	BLQ	BLQ (15 h, 21 h)	21.2 \pm 2.0	19.0, 21, 24.9 (15 h, 21 h, 23 h)	1.23 \pm 0.05
		BLQ (1 h)		24.2 (1 h)	
0.40	0.10 \pm 0.02	0.11 (15 h)	30.9 \pm 3.1	18.4 (15 h)	1.54 \pm 0.17
		0.12 (15 h)		10.2 (15 h)	
0.65	0.25 \pm 0.02	BLQ, 0.17 (1.5 h, 22 h)	33.7 \pm 4.8	30.9, 37.6 (1.5 h, 22 h)	1.38 \pm 0.28
		0.17, 0.26 (1 h, 22 h)		83.1, 22.8 (1 h, 22 h)	
1	0.37 \pm 0.06	0.25 (16 h)	29.4 \pm 2.5	41 (16 h)	1.44 \pm 0.25
		0.61, 0.88 (8 h, 13 h)		29.1, 34.2 (8 h, 13 h)	
1.65	0.54 \pm 0.07	No failures	33.8 \pm 4.8	No failures	1.64 \pm 0.17
Overall			31.8 \pm 2.3		1.41 \pm 0.08

Data are presented as mean \pm SEM.

BLQ = below level of quantification; N/A = not available.

^a Equilibrated naloxone levels were calculated as the mean value measured after 5 half-lives of drug infusion (>400 minutes).

^b Data presented are individual naloxone and morphine levels measured in patients who failed treatment at time after start of naloxone infusion.

Table 4. Twenty-Four-Hour Morphine Consumption for Male and Female Subjects

Naloxone infusion rate	24-hour morphine consumption (mg/kg)	
	Males	Females
Low	1.03 \pm 0.12	1.57 \pm 0.21
Moderate	1.22 \pm 0.06	1.51 \pm 0.15
High	1.35 \pm 0.36	1.62 \pm 0.17
Overall	1.17 \pm 0.12	1.57 \pm 0.10*

Data are presented as mean \pm SEM.

* Significantly different from overall males ($P < 0.025$).




Figure 2. Plasma morphine level as a function of morphine consumption for subjects who achieved adequate symptom control (Rx success, ●) and subjects who failed therapy (Rx failure, ○). At the time the second plasma morphine level was measured, plasma morphine level was independent of morphine consumption for patients in both groups, and average plasma morphine levels did not differ between groups (34.7 \pm 5.1 vs 29.2 \pm 3.2 ng/mL for responders and treatment failures, respectively).




Figure 3. Average self-reported pain scores for male (○) and female (●) subjects who achieved adequate symptom control. Female subjects reported significantly (*) higher pain scores than male subjects at 8, 20, and 24 hours after initiation of therapy ($P = 0.039$, $P = 0.023$, and $P = 0.002$, respectively).

the initial postoperative period, the highest plasma morphine level measured in any patient who failed therapy was 41 ng/mL.

Comparing pain scores over the first 24 hours after surgery in those patients who did not fail treatment, we found that females reported significantly higher pain scores than males at 8, 20, and 24 hours after the start of the naloxone infusion (4.9 \pm 0.5 vs 3.4 \pm 0.5, $P = 0.039$, 4.7 \pm 0.4 vs 2.9 \pm 0.6, $P = 0.023$, and 5.0 \pm 0.5 vs 2.5 \pm 0.7, $P = 0.002$, respectively) (Fig. 3). However, we did not observe any difference in analgesia in female patients over time as the naloxone infusion rate was increased. In male patients, pain scores trended lower over time in the low- and moderate-dose infusion rate groups, but not in the high-dose group. This difference was statistically significant at 24 hours, but this observation is limited by the fact that pain

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.